Patheon Inc

Patheon — FY2011 Earnings Presentation

20 slides from Patheon's earnings presentation, Dec 19, 2011

  1. Slide 1: Patheon Fiscal 2011 Results

    December Exhibit 99.2 Patheon Fiscal 2011 Results

  2. Slide 2: Forward-Looking Statements

    This presentation contains forward-looking statements or information which reflect our expectations regarding possible events, conditions, our future growth, results of operations, performance, and business prospects and opportunities. All statements, other than statements of historical fact, are fo

  3. Slide 3: Slide 3

  4. Slide 4: Slide 4

  5. Slide 5: Slide 5

  6. Slide 6: Agenda

    • 2011 Financial Results • Transformation Results • Q&A Agenda

  7. Slide 7: Fiscal 2011 Results

    Fiscal 2011 Results

  8. Slide 8: Full Year 2011 Summary

    Full Year 2011 Summary • Revenues for fiscal 2011 for Commercial Manufacturing were $572.6m up from $545.3m for fiscal 2010. Adjusted EBITDA for Commercial Manufacturing segment was $80.0m up from $72.3m for fiscal 2010. • Revenues for fiscal 2011 for Pharmaceutical Development Services were $127.4m

  9. Slide 9: Select Financial Data

    Select Financial Data This includes $32.9 M in 1Q11 and $17.5 M in 2Q11 related to deferred revenue and a reservation fee from an amended manufacturing supply agreement in the UK Quarterly results for fiscal 2011 Q1 2011 Q2 2011 Q3 2011 Q4 2011 (in millions of U.S. dollars) $ $ $ $ $ Revenues 175.7

  10. Slide 10: Our strategy is executed across four elements

    Our strategy will be executed across four elements Element I Strengthen core operations Element II Sell business differently Element III Enter adjacencies Element IV Drive industry consolidation Our strategy is executed across four elements

  11. Slide 11: Strengthen our core operations

    Operating System Mindsets, Capabilities & Behaviors Management Infrastructure The formal structures, processes and systems through which the operating system is managed to deliver the business objectives The way physical assets and resources are configured and optimized to create value and minimize

  12. Slide 12: Strengthen our Core: Operational Effectiveness

    2Q11 3Q11 4Q11 1Q12 2Q12 •Right First Time (Reduced Overtime) •Operational Flow Efficiencies & Output per Employee (ex. lab testing) •Improved Planning Process •Decreased Labor Costs •Increased Capacity (de- creased bottlenecks) •Increased throughput due to labor efficiencies •Develop Strategic Clie

  13. Slide 13: Our strategy is executed across four elements

    Element I Strengthen core operations Element II Sell business differently Element III Enter adjacencies Element IV Drive industry consolidation Our strategy is executed across four elements

  14. Slide 14: CMO Market Trends and Implications

    Source: PharmSource (2011) CMO Market Trends and Implications Competitive Landscape Trends • Highly fragmented market, and industry consolidation is progressing slowly • 3% to 5% annual growth forecasted (2011 – 2015) • CMOs continue to add capabilities/capacity despite indication of oversupply • Fr

  15. Slide 15: PDS Market Trends and Implications

    • Competition intensifies as new competitor types (e.g., CROs) have broadened their service offerings, expanding towards the PDS space • Reduced funding for emerging pharmas’ early development projects, and shrinking R&D efforts within big pharma, are forcing smaller CDOs to restructure/downsize • M

  16. Slide 16: Lessons Learned: Sell business differently

    Lessons Learned Biopharm Sell business differently Solution Based offerings that drive customer value Sterile Backup Supply SoluPath™ • Campaign messaging developed around solutions to our customers’ problems rather than our own existing capabilities • Fits a specific customer need which is currentl

  17. Slide 17: Sell the business differently – early results

    Sell the business differently – early results Sell the business differently – early results

  18. Slide 18: Principles of our Strategy

    Principles of our Strategy We will provide the industry’s leading customer experience. At all levels, places, and times our customers will have a predictably outstanding experience. Our factories must be the highest quality, most flexible, and most efficient producers in the world. Our Pharmaceutica

  19. Slide 19: Q&A

    Q&A

  20. Slide 20: Appendix: Adjusted EBITDA Bridges

    Appendix Adjusted EBITDA Bridges Q1 2011 Q2 2011 Q3 2011 Q4 2011 (in millions of U.S. dollars) $ $ $ $ $ Adjusted EBITDA 29.5 14.3 11.9 17.3 73.0 Depreciation and amortization (14.9) (13.5) (12.6) (12.4) (53.4) Repositioning expenses (0.9) (0.7) (1.9) (3.5) (7.0) Interest expense, net (6.3) (6.3) (6

Patheon — FY2011 Earnings Presentation on 6ix